We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Collaboration on Vein Imaging Technology

By MedImaging staff writers
Posted on 23 Aug 2005
Luminetx Corp. More...
(Memphis, TN, USA), a leading developer of bioscience technologies, including an infrared vein imaging system, VeinViewer, has announced a three-year distribution agreement with Diomed Holdings, Inc. (Andover, MA, USA), a developer of minimally invasive medical technologies, including its patented EVLT for varicose veins.

The agreement, which provides exclusive distribution rights to the schlerotherapy, phlebectomy, and varicose vein treatment markets in the United States and United Kingdom, includes both a U.S.$1 million investment in Luminetx and a grant of 600,000 Diomed warrants, and is expected to generate a minimum of $16 million in Luminetx revenues over the term of the agreement.

"We looked at several companies working in the schlerotherapy and phlebectomy arenas, and chose Diomed as our distribution partner because we believe they have the winning technology,” said Jim Phillips, CEO of Luminetx. "We were also very impressed with the caliber of the management team at Diomed.”

Acknowledged by Time magazine as "one of the most amazing medical inventions of the year,” VeinViewer is a breakthrough device that may transform medical procedures. The device is a venous imaging system that utilizes infrared light and other patented technologies to project a real-time image of subcutaneous veins directly onto the surface of a patient's skin. The VeinViewer is expected to be available for general distribution in
the first quarter of 2006.

The VeinViewer, cleared by the U.S. Food and Drug Administration (FDA) in 2004, is undergoing clinical assessments in both the United States and South America. Roberto Kasuo Miyake, M.D., Ph.D., a noted international researcher, schlerotherapist, and vascular surgeon at the Clinica Miyake in Sao Paulo (Brazil), commented, "VeinViewer has been a key component of our treatment protocols, and has radically improved our patient outcomes. With VeinViewer, the marks are exact, which eliminates the need for ‘fishing,' reduces additional trauma to the area, and actually allows patients to heal faster.”






Related Links:
Luminetx
Diomed Holdings

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Gold Member
Blood Gas Analyzer
i-Check200
Desk Aneroid Sphyg
Diagnostix 750D+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.